Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient~* A signed and dated written informed consent prior to study participation.~* Male or female adults.~* 40 to 80 years of age at Visit 1~* Diagnosis of COPD~* Current or former cigarette smokers with a history of cigarette smoking of greater than or equal to 10 pack-years~* Post-albuterol forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)\<0.70 and post albuterol FEV1 of greater than or equal to 35% and less than or equal to 70% of predicted normal values~Exclusion Criteria:~* Women who are pregnant or lactating or are planning on becoming pregnant during the study.~* A current diagnosis of asthma~* Known alpha-1 antitrypsin deficiency, active lung infections (such as tuberculosis), and lung cancer~* Other significant respiratory conditions in addition to COPD~* Other diseases that are uncontrolled including cancer in remission for less than 5 years~* Chest x-ray or CT scan with clinically significant abnormalities not believed to be due to the presence of COPD~* Hypersensitivity to any anticholinergic/muscarinic receptor antagonist, beta2-agonist, lactose/milk protein or magnesium stearate~* A medical condition that contraindicates study participation or use of an inhaled anticholinergic~* Hospitalization for COPD or pneumonia within 12 weeks of Visit 1~* Any previous lung resection surgery~* A body mass index (BMI) value of \>35 kilogram (kg)/meter squared (m2)~* An abnormal and significant electrocardiogram finding at Visit 1~* Significantly abnormal finding from clinical chemistry or haematology tests at Visit 1.~* A positive Hepatitis B surface antigen or positive Hepatitis C antibody~* Medically unable to withhold albuterol (salbutamol) for the 6 hour period prior to study visits~* Use of depot corticosteroids within 12 weeks of Visit 1~* Use of oral or parenteral corticosteroids or antibiotics for lower respiratory tract infection within 6 weeks of Visit 1~* Use of long-acting beta-agonist (LABA)/inhaled corticosteroid (ICS) product if LABA/ICS therapy is discontinued within 30 days of Visit 1~* Use of ICS at a dose of \>1000mcg/day of fluticasone propionate or equivalent within 30 days of Visit 1~* Initiation or discontinuation of ICS within 30 days of Visit 1~* Use of tiotropium or phosphodiesterase 4 inhibitors within 14 days of Visit 1~* Use of theophyllines, oral leukotriene inhibitors, long-acting oral beta-agonists, or inhaled long-acting beta-agonists within 48 hours of Visit 1~* Short-acting oral beta-agonists within 12 hours of Visit 1~* Use of LABA/ICS combination products only if discontinuing LABA therapy and switching to ICS monotherapy within 48 hours of Visit 1 for the LABA component~* Use of sodium cromoglycate or nedocromil sodium within 24 hours of Visit 1~* Use of inhaled short-acting beta-agonists, inhaled short-acting anticholinergics, or inhaled short-acting anticholinergic/short-acting beta-agonist combination products within 6 hours of Visit 1~* Use of any other investigational medication within 30 days or 5 drug half-lives (whichever is longer)~* Oxygen therapy prescribed for greater than 12 hours a day~* Regular use (prescribed for use every day, not for as-needed use) of short-acting bronchodilators~* Use of continuous positive airway pressure (CPAP), nocturnal positive pressure or non-invasive positive pressure ventilation (NIPPV), including use for sleep apnea.~* Acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1~* A known or suspected history of alcohol or drug abuse within 2 years prior to Visit 1~* Anyone affiliated with investigator site~* Previous use of GSK573719 or GSK53719/GW642444

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tiotropium (Type: ACTIVE_COMPARATOR): 18 mcg, inhaled long acting muscarinic antagonist
- GSK573719 (Type: EXPERIMENTAL): inhaled medication
- Placebo (Type: PLACEBO_COMPARATOR): inactive/excipients only

Based on this trial design, predict the completion outcome and termination type (if applicable).